The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.

The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.

The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.

The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.

The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.

The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.

The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.

The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $1.14, which is within the analyst’s predicted range.